Medicine
Aggrastat 3.75 mg/15 mL injection
Aggrastat 3.75 mg/15 mL injection is a prescription medicine containing Tirofiban for intravenous use, marketed by Medicure International, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store AGGRASTAT at controlled room temperature, 25°C (77°F)…
Key facts
- Active ingredient (INN)
- Tirofiban
- Brand
- Aggrastat
- Strength
- 3.75 mg/15 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 15 mL
- Marketing authorisation holder
- Medicure International
- Manufacturer
- Medicure International
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store AGGRASTAT at controlled room temperature, 25°C (77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light during storage.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B01AC17 Tirofiban
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 October 2016
- Identifiers
- RxCUI 1737466, 1737468, 1737471 +3DailyMed set ID e850111f-e713-41a2-9c65-21c517cf5511, fe0ced75-ccbf-4d2e-bd0d-b57e60ab913fNDC 25208-901, 25208-001Application NDA020912
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 15 mL in 1 vial, glass | 25208-001-04 | Medicure International | 15 October 2016 |
| 1 vial, glass in 1 carton / 15 mL in 1 vial, glass | 25208-901-04 | Medicure International | 15 October 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 14 May 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tirofiban
Clinical summary
Tirofiban is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). MedsAcross supplies Tirofiban for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TirofibanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- AGGRASTAT prescribing information (Medicure International) · U.S. National Library of Medicine, DailyMed
Need Aggrastat 3.75 mg/15 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.